跳至主要内容
临床试验/NCT00035269
NCT00035269已完成3 期

Linezolid in the Treatment of Penicillin-Resistant Streptococcus Pneumoniae Pneumonia: An Open-Label, Non-Comparator Study

Pfizer46 个研究点 分布在 4 个国家目标入组 230 人开始时间: 2001年12月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
230
试验地点
46
主要终点
To assess the microbiologic efficacy of linezolid in the treatment of patients with pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP).

研究概览

简要总结

This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
13 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must have the signs and symptoms of pneumonia, with a chest xray showing a pneumonia.
  • The patient must have S. pneumoniae (a specific bacteria) growing in sputum or blood to continue treatment.

排除标准

  • Patients cannot have taken more than one day of another antibiotic before entering this study.
  • Patients with HIV and a low CD4 count are excluded.

结局指标

主要结局

To assess the microbiologic efficacy of linezolid in the treatment of patients with pneumonia caused by penicillin-resistant Streptococcus pneumoniae (PRSP).

Additionally, microbiologic efficacy will be assessed in all pneumonia patients infected with S pneumoniae SP) and in those infected with penicillin-sensitive (PSSP) and penicillin-intermediate (PISP) S pneumoniae.

次要结局

  • To assess clinical efficacy and safety in pneumonia patients infected with S pneumoniae.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (46)

Loading locations...

相似试验